Cancers (Basel), 2020, 12(7):1-20

Mambalgin-2 Induces Cell Cycle Arrest and Apoptosis in Glioma Cells via Interaction with ASIC1a.

Gliomas are fast growing and highly invasive brain tumors, characterized by tumor microenvironment acidification that drives glioma cell growth and migration. Channels containing Acid-sensing Ion Channel 1a subunit (ASIC1a) mediate amiloride-sensitive cation influx in late stage glioma cells, but not in normal astrocytes. Thus, selective targeting of ASIC1a can be a perspective strategy for glioma treatment. Here, ASIC1a expression in U251 MG and A172 glioma cells, but not in normal astrocytes, was demonstrated. Recombinant analog of mambalgin-2 from black mamba inhibited amiloride-sensitive currents at ASIC1a both in oocytes and in U251 MG cells, while its mutants with impaired activity towards this channel did not. Mambalgin-2 inhibited U251 MG and A172 glioma cells growth with EC in the nanomolar range without affecting the proliferation of normal astrocytes. Notably, mambalgin-2 mutants did not affect glioma cell proliferation, pointing on ASIC1a as the main molecular target of mambalgin-2 in U251 MG and A172 cells. Mambalgin-2 induced a cell cycle arrest, inhibited Cyclin D1 and cyclin-dependent kinases (CDK) phosphorylation and caused apoptosis in U251 MG and A172 cells. Moreover, mambalgin-2 inhibited the growth of low-passage primary cells from a patient with glioblastoma. Altogether, our data point to mambalgin-2 as a useful hit for the development of new drugs for glioma treatment.

IBCH: 8677
Ссылка на статью в журнале: https://www.mdpi.com/2072-6694/12/7/1837
Кол-во цитирований на 09.2023: 18
Данные статьи проверены модераторами 2020-07-14

Список научных проектов, где отмечена публикация

  1. Изучение молекулярных механизмов, лежащих в основе противоопухолевой активности трехпетельного токсина мамбалгина-2 (27 Апреля 2018 года — 9 Апреля 2020 года). Бычков М.Л.. Грант, РФФИ.
  2. Новые подходы для таргетной терапии глиом на основе профилирования опухолей по биохимическим маркерам, биофизическим свойствам клеток и метаболической активности (16 Июля 2018 года — 16 Июля 2021 года). Шенкарёв З.О.. Грант, РФФИ.